Rigel Financial Statements From 2010 to 2025

RIGL Stock  USD 20.33  0.70  3.33%   
Rigel Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Rigel Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Rigel Pharmaceuticals financial statements helps investors assess Rigel Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Rigel Pharmaceuticals' valuation are summarized below:
Gross Profit
137.3 M
Profit Margin
0.0975
Market Capitalization
375.7 M
Enterprise Value Revenue
1.9084
Revenue
179.3 M
There are over one hundred nineteen available trending fundamental ratios for Rigel Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to check out Rigel Pharmaceuticals' recent fundamental drivers against the all of the trends between 2010 and 2025. The value of Market Cap is estimated to slide to about 275.7 M. The Enterprise Value is projected to slide to about 306 M

Rigel Pharmaceuticals Total Revenue

188.24 Million

Check Rigel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rigel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 8.3 M or Total Revenue of 188.2 M, as well as many indicators such as Price To Sales Ratio of 1.57, Dividend Yield of 0.0 or PTB Ratio of 94.42. Rigel financial statements analysis is a perfect complement when working with Rigel Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Rigel Pharmaceuticals Correlation against competitors.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.

Rigel Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets144.3 M164 M151.1 M
Pretty Stable
Short and Long Term Debt Total63 M60 M26.4 M
Slightly volatile
Other Current Liabilities53.6 M51 M22.5 M
Slightly volatile
Total Current Liabilities66.5 M63.3 M35.7 M
Slightly volatile
Property Plant And Equipment Net321.1 K338 KM
Very volatile
Accounts Payable4.3 M3.3 M4.7 M
Slightly volatile
Cash33.9 M56.7 M30.6 M
Slightly volatile
Non Current Assets Total30.3 M28.9 M12.5 M
Slightly volatile
Non Currrent Assets Other1.2 M1.4 M1.2 M
Pretty Stable
Cash And Short Term Investments120.7 M77.3 M121.6 M
Slightly volatile
Net Receivables43.7 M41.6 M14.7 M
Slightly volatile
Common Stock Total Equity210.1 K200.1 K131.8 K
Slightly volatile
Common Stock Shares Outstanding16.8 M17.7 M65.8 M
Slightly volatile
Liabilities And Stockholders Equity144.3 M164 M151.1 M
Pretty Stable
Non Current Liabilities Total102.3 M97.4 M35.8 M
Slightly volatile
Other Current Assets10.7 M10.2 M5.9 M
Slightly volatile
Other Stockholder Equity893.5 M1.4 B1.1 B
Slightly volatile
Total Liabilities168.7 M160.7 M71.5 M
Slightly volatile
Property Plant And Equipment Gross569 K599 K7.7 M
Pretty Stable
Total Current Assets134.2 M135.1 M139.9 M
Slightly volatile
Short Term Debt4.9 M7.6 M6.5 M
Slightly volatile
Common Stock17.1 K18 K108.4 K
Slightly volatile
Other Liabilities63.7 M60.6 M21.4 M
Slightly volatile
Other Assets547.2 K576 K932.3 K
Slightly volatile
Short Term Investments19.5 M20.6 M87.1 M
Slightly volatile
Property Plant Equipment732.7 K771.3 K3.2 M
Slightly volatile
Capital Surpluse1.3 B1.6 B1.2 B
Slightly volatile
Deferred Long Term Liabilities77 K81 K3.4 M
Slightly volatile
Non Current Liabilities Other47.2 M45 M15.2 M
Slightly volatile
Net Invested Capital49.8 M63 M78.3 M
Slightly volatile
Net Working Capital57.7 M71.8 M83 M
Slightly volatile
Capital Stock17.1 K18 K149.8 K
Slightly volatile
Long Term Debt Total24.5 M45.4 M17.9 M
Slightly volatile
Capital Lease Obligations270.8 K285 K18.7 M
Slightly volatile
Short and Long Term DebtM7.3 M7.3 M
Slightly volatile

Rigel Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M2.2 M1.6 M
Slightly volatile
Total Revenue188.2 M179.3 M65.7 M
Slightly volatile
Other Operating Expenses105 M155.1 M110.7 M
Slightly volatile
Research Development22.2 M23.4 M52.3 M
Slightly volatile
Total Operating Expenses104.1 M136.4 M108.8 M
Slightly volatile
Selling General Administrative118.7 M113.1 M59.2 M
Slightly volatile
Non Operating Income Net Other936.5 K786.6 K815.2 K
Pretty Stable
Non Recurring1.1 M1.2 M2.9 M
Pretty Stable
Interest Income1.3 M2.1 M882 K
Slightly volatile
Reconciled Depreciation2.3 M2.2 M853.7 K
Slightly volatile

Rigel Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow31.9 M32.8 M27.7 M
Slightly volatile
Depreciation1.7 M2.2 M1.5 M
Slightly volatile
Capital Expenditures34.2 K36 K2.2 M
Very volatile
End Period Cash Flow33.9 M56.7 M30.6 M
Slightly volatile
Stock Based Compensation8.9 M12.4 MM
Pretty Stable
Change To Netincome7.6 M11.8 M9.9 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.571.6493215
Slightly volatile
Days Sales Outstanding64.1584.7258116
Slightly volatile
Stock Based Compensation To Revenue0.06570.06910.8537
Slightly volatile
Capex To Depreciation0.01540.01621.7147
Pretty Stable
EV To Sales1.581.6672213
Slightly volatile
Inventory Turnover3.263.10680.7572
Slightly volatile
Days Of Inventory On Hand112117721
Pretty Stable
Sales General And Administrative To Revenue1.341.422.7573
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue0.120.13045.6101
Slightly volatile
Capex To Revenue2.0E-42.0E-40.2055
Slightly volatile
Cash Per Share4.184.398517.9666
Slightly volatile
Intangibles To Total Assets0.10.16530.1144
Slightly volatile
Current Ratio2.032.13447.0309
Slightly volatile
Receivables Turnover4.094.30813.8499
Pretty Stable
Graham Number2.242.352.4011
Slightly volatile
Capex Per Share0.00190.00212.8307
Slightly volatile
Revenue Per Share16.110.198420.4631
Slightly volatile
Interest Debt Per Share3.673.861615.3188
Slightly volatile
Debt To Assets0.380.36570.2114
Slightly volatile
Operating Cycle354202706
Slightly volatile
Ebt Per Ebit0.820.75921.0449
Pretty Stable
Long Term Debt To Capitalization0.540.9410.5154
Slightly volatile
Total Debt To Capitalization1.00.9480.5301
Slightly volatile
Quick Ratio1.942.03956.9917
Slightly volatile
Net Income Per E B T0.810.860.9802
Slightly volatile
Cash Ratio0.850.89651.1971
Slightly volatile
Days Of Inventory Outstanding112117721
Pretty Stable
Days Of Sales Outstanding64.1584.7258116
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.940.99891.2226
Pretty Stable
Fixed Asset Turnover55753084.028
Slightly volatile
Debt Ratio0.380.36570.2114
Slightly volatile
Price Sales Ratio1.571.6493215
Slightly volatile
Asset Turnover1.151.09330.4928
Slightly volatile

Rigel Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap275.7 M290.2 M345.8 M
Slightly volatile
Enterprise Value306 M322.1 M343.6 M
Pretty Stable

Rigel Fundamental Market Drivers

Forward Price Earnings22.8833
Cash And Short Term Investments77.3 M

Rigel Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Rigel Pharmaceuticals Financial Statements

Rigel Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Rigel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.6 M1.5 M
Total Revenue179.3 M188.2 M
Cost Of Revenue18.6 M17.7 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 1.42  1.34 
Research And Ddevelopement To Revenue 0.13  0.12 
Revenue Per Share 10.20  16.10 
Ebit Per Revenue 0.13  0.14 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:
Check out the analysis of Rigel Pharmaceuticals Correlation against competitors.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
17.867
Earnings Share
0.99
Revenue Per Share
10.198
Quarterly Revenue Growth
0.609
Return On Assets
0.1075
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.